Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes

Table 2 Association between age and mortality corrected for statin treatment, testosterone status/treatment and phosphodiesterase 5-inhibitors treatment

	OR (95%CI)	P value
Model a
Age (yr)	1.10 (1.08-1.13)	< 0.001
Model b
Age (yr)	1.10 (1.07-1.13)	< 0.001
Statin/untreated	Reference
Statin/treated	0.63 (0.39-1.01)	0.057
Model c
Age (yr)	1.10 (1.07-1.12)	< 0.001
Normal T/untreated	0.61 (0.42-1.07)	0.092
Low T/untreated	Reference
Low T/treated	0.31 (0.13-0.75)	0.009
Model d
Age (yr)	1.09 (1.07-1.12)	< 0.001
PDE5I/untreated	Reference
PDE5I/treated	0.16 (0.051-0.54)	0.003
Model e
Age (yr)	1.08 (1.06-1.11)	< 0.001
Statin/untreated	Reference
Statin/treated	0.59 (0.36-0.97)	0.038
Normal T/untreated	0.69 (0.43-1.10)	0.120
Low T/untreated	Reference
Low T/treated	0.38 (0.15-0.92)	0.033
PDE5I/untreated	Reference
PDE5I/treated	0.17 (0.053-0.56)	0.004

PDE5I: Phosphodiesterase 5-inhibitors.